A study of concentrations of trimethoprim-sulphamethoxazole in the human prostate gland.
The ability of trimethoprim (TMP) and sulphamethoxazole (SMX) components of co-trimoxazole to penetrate the human prostate gland was investigated. After a single 4-tablet dose TMP was evenly distributed between prostate and plasma, whereas SMX was mainly associated with plasma. Following a week's therapy significant accumulation of TMP was seen in the prostate relative to plasma whereas SMX although still associated with plasma had increased drug levels in prostate compared with the single dose study. It is concluded that co-trimoxazole produces effective antibacterial levels in the human prostate and has indications in the treatment of prostatitis.
D006801:Humans; D008297:Male; D011467:Prostate / Q000032:analysis* / Q000378:metabolism; D011468:Prostatectomy; D013420:Sulfamethoxazole / Q000032:analysis* / Q000097:blood / Q000378:metabolism; D014295:Trimethoprim / Q000032:analysis* / Q000097:blood / Q000378:metabolism
D014295:Trimethoprim; D013420:Sulfamethoxazole